Literature DB >> 24402404

New daily persistent headache and potential new therapeutic agents.

Shivang G Joshi1, Paul G Mathew, Herbert G Markley.   

Abstract

New daily persistent headache is a form of a chronic daily headache with a unique temporal profile. Patients can recall the exact day when their headache started. It can be one of the most refractory types of headache to treat. Recent publications have highlighted different subtypes and heterogeneity in presentation. Referring to it as a syndrome versus a distinct disorder has also been suggested. Several different classes of medications have been used for the treatment, with mixed results. The underlying pathophysiology of new daily persistent headache is unclear, but tumor necrosis factor may play a role. The clinical features, differential diagnosis and potential new therapeutic agents will be discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24402404     DOI: 10.1007/s11910-013-0425-5

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  31 in total

Review 1.  New daily persistent headache.

Authors:  Todd D Rozen
Journal:  Curr Pain Headache Rep       Date:  2003-06

2.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

3.  Headache in Ehlers-Danlos syndrome.

Authors:  D E Jacome
Journal:  Cephalalgia       Date:  1999-11       Impact factor: 6.292

4.  Improving sleep: initial headache treatment in OIF/OEF veterans with blast-induced mild traumatic brain injury.

Authors:  Robert L Ruff; Suzanne S Ruff; Xiao-Feng Wang
Journal:  J Rehabil Res Dev       Date:  2009

5.  Cervical spine joint hypermobility: a possible predisposing factor for new daily persistent headache.

Authors:  T D Rozen; J M Roth; N Denenberg
Journal:  Cephalalgia       Date:  2006-10       Impact factor: 6.292

6.  Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.

Authors:  Jarred Younger; Sean Mackey
Journal:  Pain Med       Date:  2009-04-22       Impact factor: 3.750

7.  The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production.

Authors:  Kristy M Greeneltch; Christian C Haudenschild; Achsah D Keegan; Yufang Shi
Journal:  Brain Behav Immun       Date:  2004-09       Impact factor: 7.217

8.  Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases.

Authors:  Alan M Rapoport; Marcelo E Bigal; Michel Volcy; Fred D Sheftell; Michele Feleppa; Stewart J Tepper
Journal:  Headache       Date:  2003-05       Impact factor: 5.887

9.  Juvenile myoclonic epilepsy presenting as a new daily persistent-like headache.

Authors:  Todd D Rozen
Journal:  J Headache Pain       Date:  2011-07-08       Impact factor: 7.277

10.  Efficacy of botulinum toxin type A in new daily persistent headache.

Authors:  Roderick C Spears
Journal:  J Headache Pain       Date:  2008-10-25       Impact factor: 7.277

View more
  3 in total

1.  Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents.

Authors:  Christina L Szperka; Juliana VanderPluym; Serena L Orr; Christopher B Oakley; William Qubty; Irene Patniyot; Ana Marissa Lagman-Bartolome; Cynthia Morris; Jessica Gautreaux; M Cristina Victorio; Suzanne Hagler; Sona Narula; Meghan S Candee; Catalina Cleves-Bayon; Rashmi Rao; Robert H Fryer; Alma R Bicknese; Marcy Yonker; Andrew D Hershey; Scott W Powers; Peter J Goadsby; Amy A Gelfand
Journal:  Headache       Date:  2018-10-15       Impact factor: 5.887

Review 2.  The Enigma of New Daily Persistent Headache: What Solutions for Pediatric Age?

Authors:  Laura Papetti; Giorgia Sforza; Ilaria Frattale; Samuela Tarantino; Fabiana Ursitti; Michela Ada Noris Ferilli; Federico Vigevano; Massimiliano Valeriani
Journal:  Curr Pain Headache Rep       Date:  2022-01-22

Review 3.  Update on New Daily Persistent Headache.

Authors:  Hida Nierenburg; Lawrence C Newman
Journal:  Curr Treat Options Neurol       Date:  2016-06       Impact factor: 3.972

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.